Literature DB >> 12568401

Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen.

Joan C Marini1, Elizabeth Hopkins, Francis H Glorieux, George P Chrousos, James C Reynolds, Caren M Gundberg, C Michael Reing.   

Abstract

Extreme short stature is a cardinal feature of severe osteogenesis imperfecta (OI), types III and IV. We conducted a treatment trial of growth hormone in children with OI and followed linear growth velocity, bone metabolism markers, histomorphometrics, and vertebral bone density. Twenty-six children with types III and IV OI, ages 4.5-12 years, were treated with recombinant growth hormone (rGH), 0.1-0.2 IU/kg per day for 6 days/week, for at least 1 year. Length, insulin-like growth factor (IGF-I), insulin-like growth factor binding protein (IGFBP-3), bone metabolic markers, and vertebral bone density by DXA were evaluated at 6-month intervals. An iliac crest biopsy was obtained at baseline and 12 months. Approximately one-half of the treated OI children sustained a 50% or more increase in linear growth over their baseline growth rate. Most responders (10 of 14) had moderate type IV OI. All participants had positive IGF-I, IGFBP-3, osteocalcin, and bone-specific alkaline phosphatase responses. Only the linear growth responders had a significant increase in vertebral DXA z-score and a significant decrease in long bone fractures. After 1 year of treatment, responders' iliac crest biopsy showed significant increases in cancellous bone volume, trabecular number, and bone formation rate. Responders were distinguished from nonresponders by higher baseline carboxyterminal propeptide (PICP) values (p < 0.05), suggesting they have an intrinsically higher capacity for collagen production. The results show that growth hormone can cause a sustained increase in the linear growth rate of children with OI, despite the abnormal collagen in their bone matrix. In the first year of treatment, growth responders achieve increased bone formation rate and density, and decreased fracture rates. The baseline plasma concentration of PICP was an excellent predictor of positive response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12568401     DOI: 10.1359/jbmr.2003.18.2.237

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  28 in total

Review 1.  Treatment of children with osteogenesis imperfecta.

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Curr Osteoporos Rep       Date:  2006-12       Impact factor: 5.096

Review 2.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

3.  Multiple Fractures in Neonates and Osteogenesis Imperfecta.

Authors:  B M John; S K Patnaik; R W Thergaonkar
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 4.  Osteogenesis imperfecta: advancements in genetics and treatment.

Authors:  Vittoria Rossi; Brendan Lee; Ronit Marom
Journal:  Curr Opin Pediatr       Date:  2019-12       Impact factor: 2.856

5.  Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms.

Authors:  Satoru Otsuru; Patricia L Gordon; Kengo Shimono; Reena Jethva; Roberta Marino; Charlotte L Phillips; Ted J Hofmann; Elena Veronesi; Massimo Dominici; Masahiro Iwamoto; Edwin M Horwitz
Journal:  Blood       Date:  2012-07-24       Impact factor: 22.113

Review 6.  Osteogenesis imperfecta: an update on clinical features and therapies.

Authors:  Ronit Marom; Brien M Rabenhorst; Roy Morello
Journal:  Eur J Endocrinol       Date:  2020-10       Impact factor: 6.664

7.  Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.

Authors:  Benjamin P Sinder; Joseph D Salemi; Michael S Ominsky; Michelle S Caird; Joan C Marini; Kenneth M Kozloff
Journal:  Bone       Date:  2014-10-23       Impact factor: 4.398

8.  Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors.

Authors:  Thomas E Uveges; Patricia Collin-Osdoby; Wayne A Cabral; Felicia Ledgard; Leah Goldberg; Clemens Bergwitz; Antonella Forlino; Philip Osdoby; Gloria A Gronowicz; Joan C Marini
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

Review 9.  Osteogenesis Imperfecta: update on presentation and management.

Authors:  Moira S Cheung; Francis H Glorieux
Journal:  Rev Endocr Metab Disord       Date:  2008-04-11       Impact factor: 6.514

10.  Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.

Authors:  Benjamin P Sinder; Mary M Eddy; Michael S Ominsky; Michelle S Caird; Joan C Marini; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.